Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M413434200 on May 31, 2005

J. Biol. Chem., Vol. 280, Issue 32, 28885-28893, August 12, 2005
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/32/28885    most recent
M413434200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sayasith, K.
Right arrow Articles by Sirois, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sayasith, K.
Right arrow Articles by Sirois, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Role of Upstream Stimulatory Factor Phosphorylation in the Regulation of the Prostaglandin G/H Synthase-2 Promoter in Granulosa Cells*

Khampoune Sayasith, Jacques G. Lussier, and Jean Sirois{ddagger}

From the Centre de Recherche en Reproduction Animale and the Département de Biomédecine Vétérinaire, Faculté de Médecine Vétérinaire, Université de Montréal, Saint-Hyacinthe, Québec J2S 7C6, Canada

Received for publication, November 29, 2004 , and in revised form, May 26, 2005.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
To investigate the role of USF phosphorylation in the regulation of the PGHS-2 promoter in granulosa cells, promoter activity assays were performed in primary cultures of bovine granulosa cells transfected with the chimeric PGHS-2 promoter/luciferase (LUC) construct –149/–2PGHS-2.LUC. Transfections were done in the absence or presence of forskolin; the protein kinase A (PKA) inhibitor H-89; or an expression vector encoding USF1, USF2, the catalytic subunit of PKA (cPKA), or a PKA inhibitor protein (PKI). Electrophoretic mobility shift assays were performed to study USF/DNA interactions using granulosa cell nuclear extracts and a 32P-labeled proximal PGHS-2 promoter fragment containing the E-box element. The results show that forskolin stimulation and cPKA overexpression caused a marked and significant increase in USF-dependent DNA binding and PGHS-2 promoter activities (p < 0.05). In contrast, both activities were decreased by H-89 treatment or PKI overexpression. Reverse transcription-PCR analyses revealed that these treatments had similar effects on endogenous PGHS-2 mRNA levels in granulosa cells. Cotransfection studies with a USF2 mutant lacking N-terminal activation domains (U2{Delta}1–220) repressed forskolin-, cPKA-, and USF-dependent PGHS-2 promoter activities. Electrophoretic mobility shift assays showed that U2{Delta}1–220 was able to compete with full-length USF proteins and to saturate the E-box element. Immunoprecipitation/Western blot analyses revealed an increase in the levels of phosphorylated USF1 and USF2 after forskolin treatment, whereas chromatin immunoprecipitation assays showed that binding of USF proteins to the endogenous PGHS-2 promoter was stimulated by forskolin. Site-directed mutagenesis of a consensus PKA phosphorylation site within USF proteins abolished their transactivating capacity. Collectively, these results characterize the role of USF phosphorylation in PGHS-2 expression and identify the phosphorylation-dependent increase in USF binding to the E-box as a putative molecular basis for the increase in PGHS-2 promoter transactivation in granulosa cells.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Prostaglandins are important regulators of a number of biological processes, including ovulation, which involves a complex series of biochemical events culminating in the rupture of the preovulatory follicle (1–3). Evidence for a relationship between prostaglandins and ovulation emerged in the 1970s, when studies in a number of species revealed a marked increase in the levels of follicular prostaglandins just prior to ovulation and the ability of indomethacin to block ovulation (reviewed in Refs. 1 and 4). Subsequent investigations in rats showed that this preovulatory rise in follicular prostaglandin synthesis results from gonadotropin-dependent, cell type-specific induction of prostaglandin G/H synthase (PGHS),1 the first rate-limiting enzyme in prostaglandin biosynthesis from arachidonic acid, in granulosa cells (5–7). Purification and N-terminal sequencing of the PGHS enzyme induced in rat granulosa cells helped characterize the presence and physiological significance of a then distinct PGHS isoform, now known as PGHS-2 (also referred to as cyclooxygenase-2) (8). The selective induction of PGHS-2 in rat preovulatory follicles proved to be a conserved mechanism by which the synthesis of prostaglandins necessary for ovulation is regulated in different species (9–15). Ultimately, genetic studies underscored the essential role of the enzyme in ovulation, as mice deficient in PGHS-2 have an anovulatory phenotype that can be reversed with exogenous prostaglandin E2 (16–18). Interestingly, the genetic background of the PGHS-2-null mice was shown to markedly influence the anovulatory/ovulatory phenotype (19).

The gonadotropin-dependent induction of PGHS-2 observed in preovulatory follicles in vivo has been recapitulated in vitro, as numerous agonists acting primarily through the protein kinase A (PKA) pathway were shown to increase expression of the PGHS-2 transcript and protein in primary cultures of granulosa cells (7, 9, 11, 20, 21). Incubation with the transcriptional inhibitor {alpha}-amanitin abolishes the agonist-dependent increase in PGHS-2 expression, clearly indicating that the phenomenon is dependent on transcription (20). The cloning of the rat and bovine PGHS-2 promoters and their characterization using homologous granulosa cell cultures revealed in both species that the proximal 150–200 bp located upstream of the transcriptional start site are sufficient to confer basal and forskolin/gonadotropin-inducible promoter activities (21, 22). Although a number of consensus cis-acting elements were identified within this proximal region, site-directed mutagenesis identified the E-box element as the predominant element involved in the regulation of PGHS-2 promoter activities in preovulatory granulosa cells (21, 23).

Upstream stimulatory factor (USF) 1 and USF2 are ubiquitous proteins characterized by highly conserved C-terminal basic helix-loop-helix and leucine zipper domains responsible for dimerization and DNA binding activities (24, 25). These transactivating factors are known to bind to the E-box promoter element and to regulate the transcription of several genes (26–32). Immunoblotting and electrophoretic mobility shift assays (EMSAs) provided evidence for the presence of USF proteins in granulosa cell nuclear extracts and for their ability to interact with the E-box element present in the PGHS-2 promoter (21, 23). More direct evidence for a role of USF proteins in PGHS-2 promoter transactivation came from the demonstration that overexpression of full-length USF proteins markedly increases and overexpression of a dominant-negative USF2 mutant represses PGHS-2 promoter activities in a E-box-dependent manner in granulosa cells (33). However, the absence of changes in the endogenous levels of full-length USF proteins during the ovulatory process in rat and bovine granulosa cells (21, 23) raises questions as to the precise mechanism controlling USF-dependent PGHS-2 activation. Considering that USF phosphorylation has been implicated in modulating the DNA binding and transcriptional activities of other genes (34–36), the specific objective of the present study was to determine the potential role of USF phosphorylation in the regulation of the PGHS-2 promoter in preovulatory granulosa cells.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Materials—[{alpha}-32P]dCTP was purchased from PerkinElmer Life Sciences (Woodbridge, Ontario, Canada). Lipofectamine Plus reagent, TRIzol total RNA isolation reagent, a 1-kb DNA ladder, synthetic oligonucleotides, and culture medium were obtained from Invitrogen (Burlington, Ontario). Fetal bovine serum was purchased from Hyclone Laboratories (Logan, UT). The 5'-end labeling system, the Dual-Luciferase reporter assay system, and plasmids pGEM-T Easy and pGL3-Basic were obtained from Promega Corp. (Madison, WI). Hybond-P polyvinylidene difluoride membranes, Rainbow molecular weight markers, the ECL Plus Western blotting system, horseradish peroxidase-linked donkey anti-rabbit secondary antibody, and restriction enzymes were obtained from Amersham Biosciences (Baie D'Urfé, Québec, Canada). Polyclonal antibodies against USF1 and USF2 and protein A/G-Sepharose beads were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Phosphatase type VII-S, 8-bromo-cAMP (8-Br-cAMP), aprotinin, leupeptin, antipain, benzamidine, chymotrypsin, pepstatin, and monoclonal antibodies against phosphoserine and phosphothreonine were purchased from Sigma (Oakville, Ontario). Proteinase K and the One-Step RT-PCR system were purchased from Qiagen Inc. (Mississauga, Ontario). Forskolin and the PKA inhibitor H-89 were obtained from Calbiochem. The QuikChange site-directed mutagenesis kit was purchased from Stratagene (La Jolla, CA). Expression constructs for the catalytic subunit of PKA (cPKA), the PKA inhibitor protein (PKI), Ca2+/calmodulin-dependent protein kinase (CaMK) II, and CaMKIV were generously provided by Dr. Richard Maurer (Oregon Health and Science University, Portland, OR).

Bovine USF cDNA and PGHS-2 Promoter Constructs—Expression constructs containing full-length USF proteins (referred to as wild-type (wt) USF1 (U1wt) and USF2 (U2wt)) and constructs encoding N-terminally truncated forms of USF1 (U1{Delta}1–129, which lacks residues 1–129) and USF2 (U2{Delta}1–220, which lacks residues 1–220) were produced by PCR and subcloned into pcDNA3.1(+) (Invitrogen) as described previously (33). Full-length USF constructs containing a single point mutation were produced to generate mutants in which a putative phosphorylatable serine residue was replaced with a non-phosphorylatable alanine residue. These mutants were made with the QuikChange site-directed mutagenesis kit following the manufacturer's protocol using the U1wt or U2wt construct as template and the mutagenic oligonucleotide primers described under "Results." For USF1 mutants, the amino acid switch was performed at Ser257 or Ser262, and the constructs were named U1S257A and U1S262A, respectively. For USF2 constructs, the amino acid switch was performed at Ser259, Ser269, or Ser275, and the constructs were named U2S259A, U2S269A, and U2S275A, respectively. All mutants were confirmed by DNA sequencing.

The production of the chimeric bovine PGHS-2 promoter/firefly luciferase (LUC) constructs –149/–2PGHS-2.LUC and –149/–2PGHS-2{Delta}E-box.LUC has been described previously (21). The –149/–2PGHS-2.LUC construct was produced by subcloning the –149/–2 PGHS-2 promoter fragment (where +1 is the transcriptional start site) upstream of the firefly luciferase reporter gene in the pGL3-Basic vector, whereas the –149/–2PGHS-2{Delta}E-box.LUC construct was designed to contain a mutated E-box element in the context of the –149/–2 PGHS-2 promoter fragment (21).

Cell Culture, Transient Transfections, and Reporter Activity Assays— Primary cultures of bovine granulosa cells, transient transfections, and reporter activity assays were performed as described previously (21, 33). Briefly, cells were seeded at a density of 1–2 x 105 cells/well in 24-well plates containing 0.5 ml of minimal essential medium supplemented with L-glutamine, nonessential amino acids, 2% fetal bovine serum, 1 µg/ml insulin, 5 µg/ml transferrin, 100 units/ml penicillin, and 100 µg/ml streptomycin and incubated at 37 °C in a humidified atmosphere of 5% CO2. Cells were transiently transfected with –149/–2PGHS-2.LUC or –149/–2PGHS-2{Delta}E-box.LUC (90 fmol/well) in the absence or presence of the USF, cPKA, PKI, CaMKII, or CaMKIV expression construct (10 fmol/well) using 2 µg of Lipofectamine Plus reagent in 0.3 ml of minimal essential medium following the manufacturer's protocol. In all cases, cotransfection with the SV40 Renilla luciferase control vector (pRL-SV40) was performed to normalize results. Three hours after transfection, cells were incubated in fresh culture medium for 36 h in the absence (control) or presence of forskolin (10 µM), 8-Br-cAMP (1 mM), or phorbol 12-myristate 13-acetate (PMA; 100 nM). After the culture period, cell lysates were prepared, and firefly and Renilla luciferase activities were determined using the Dual-Luciferase assay system and a Lumat LB 9507 luminometer (Berthold Technologies).

Granulosa Cell Nuclear Extracts and EMSAs—Confluent cultures of granulosa cells (100-mm dish) were transfected with the U1wt, U2wt, U1{Delta}1–129, or U2{Delta}1–220 expression construct (4 µg of construct/dish) using 30 µg of Lipofectamine Plus reagent following the manufacturer's protocol. Three hours after transfection, cells were incubated in fresh culture medium in the absence (control) or presence of forskolin (10 µM). Twenty-four hours after incubation, cells were harvested, and nuclear extracts were prepared as described previously (21, 22, 33). Protein concentration was determined by the method of Bradford (37) using the Bio-Rad protein assay. EMSAs were performed as described (21, 33). In some experiments, extracts were preincubated for 10 min with phosphatase type VII-S (0.5–1 IU) prior to addition of other reagents to study the effect of protein dephosphorylation on binding activities.

Chromatin Immunoprecipitation (ChIP)—ChIP assays were performed as described previously (29) with minor modifications. Briefly, untransfected granulosa cells or granulosa cells transfected with the U2wt or U2{Delta}1–220 expression construct were cultured for 36 h in the absence (control) or presence of forskolin (10 µM). At the end of the culture period, protein/DNA cross-linking was performed by incubating cells with minimal essential medium containing 1% formaldehyde for 20 min at 37 °C. Cells were harvested in phosphate-buffered saline containing 1% SDS, 10 mM Tris-HCl (pH 8.0), 0.5 mM dithiothreitol, protease inhibitors (15 µg/ml aprotinin, 1 µg/ml leupeptin, 2 µg/ml antipain, 10 µg/ml benzamidine, 1 µg/ml chymotrypsin, and 1 µg/ml pepstatin), and 1 mM phenylmethylsulfonyl fluoride. Cell lysates were sonicated (five cycles, 10 s/cycle) using a Branson Model 450 Sonifier to obtain DNA fragments of 0.5–1 kb, and debris were removed by low speed centrifugation. For each chromatin extract supernatant, one-third was kept as DNA input (positive control for DNA); one-third was incubated with anti-USF2 antibody (Santa Cruz Biotechnology, Inc.); and the remaining third was incubated with normal rabbit serum (negative control). After overnight incubation at 4 °C, lysates were incubated with protein A/G-Sepharose beads for 2 h and subsequently washed five times with phosphate-buffered saline by repeated centrifugation/resuspension cycles. Beads were incubated at 65 °C for 4 h and treated with proteinase K for 2 h at 50 °C to reverse protein/DNA cross-links. DNA was recovered by phenol/chloroform extraction and ethanol precipitation, and PCR was performed using sense (5'-TCCTA CCCCA ACCCG GGTCT TGCGC AATTG TT-3') and antisense (5'-CTCTG ACGTT CACTG CGAGT CC-3') primers specific for the bovine PGHS-2 promoter. The expected PCR product (180 bp), which contains the USF-binding E-box cis-element, was analyzed by 2% agarose gel electrophoresis.

RNA Extraction and Reverse Transcription-PCR Analysis—Total RNA was extracted from granulosa cells cultured under various experimental conditions using TRIzol reagent. The One-Step RT-PCR system was used to characterize expression of bovine USF1, USF2, PGHS-2, and glyceraldehyde-3-phosphate dehydrogenase mRNAs. Reactions were performed as described previously (33) with sense and antisense primers specific for USF1 (5'-CGTTC ACGAG TGATG ATGCG G-3' and 5'-CTCTT GATGA CAACC TCTAC TCC-3', generating a 627-bp fragment), USF2 (5'-GCGTC CAGTG TGGGA GATAC C-3' and 5'-CATGG TAGGT GGTTC ACTGC C-3', generating a 541-bp fragment), PGHS-2 (5'-CACAG TGCAC TACAT ACTTA CCC-3' and 5'-GTCTG GAACA ACTGC TCATC GC-3', generating a 735-bp fragment), and glyceraldehyde-3-phosphate dehydrogenase (5'-TGTTC CAGTA TGATC CACCC-3' and 5'-TCCAC CACCC TGTTG CTGTA-3', generating a 850-bp fragment).

Immunoprecipitation/Western Blotting—Nuclear extracts were prepared as described (21, 22, 33) from cultures of granulosa cell untransfected or transfected with the U1wt, U1{Delta}1–129, U2wt, or U2{Delta}1–220 expression construct and cultured for 36 h in the absence or presence of forskolin (10 µM). Nuclear extracts were also prepared from granulosa cells of bovine preovulatory follicles obtained from animals ovariectomized 0 and 18 h after the administration of an ovulatory dose of human chorionic gonadotropin (hCG) as described (21, 38). Immunoprecipitation was performed as described previously (39, 40) using specific anti-USF1 and anti-USF2 antibodies or normal rabbit serum (negative control). Reactions were resolved by one-dimensional SDS-PAGE and electrophoretically transferred to polyvinylidene difluoride membranes (21, 33). Membranes were incubated with anti-phosphothreonine (1:500 dilution) or anti-phosphoserine (1:500 dilution) antibody, and immunoreactive proteins were visualized by incubation with horseradish peroxidase-linked donkey anti-rabbit secondary antibody (1:5000 dilution) and the ECL Plus Western blotting system according to the manufacturer's instructions.

Statistical Analysis—One-way analysis of variance was used to test the effect of different treatments and constructs on reporter gene activities. When the results indicated significant differences (p < 0.05), Dunnett's test was used for multiple comparisons of means. Statistical analyses were performed using JMP software (SAS Institute Inc., Cary, NC).


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
PKA Pathway-dependent Control of USF-regulated PGHS-2 Promoter Activities in Granulosa Cells—To characterize the role of the PKA pathway in basal and USF-regulated PGHS-2 promoter activities, granulosa cells were cotransfected with the promoter construct –149/–2PGHS-2.LUC and the vector expressing USF1 or USF2, and cells were cultured in the absence or presence of a PKA activator (forskolin or 8-Br-cAMP) and inhibitor (H-89) and a protein kinase C activator (PMA). The results show that forskolin and 8-Br-cAMP significantly increased basal PGHS-2 promoter activity (3.3 ± 0.4 (control) versus 6.2 ± 0.5 (forskolin) and 5.5 ± 0.4 (8-Br-cAMP); p < 0.05), whereas the phorbol ester PMA had no effect in cells not overexpressing USF proteins (Fig. 1A). Cotransfections with the USF1 or USF2 expression vector resulted in an increase in basal promoter activity, which was further stimulated by forskolin and 8-Br-cAMP, but not by PMA (Fig. 1A). Incubation of cells with the PKA inhibitor H-89 blocked forskolin-stimulated PGHS-2 promoter activity in untransfected granulosa cells or in those transfected with the USF1 and USF2 expression vectors (Fig. 1B). Interestingly, H-89 also reduced USF1- and USF2-regulated PGHS-2 promoter activities in cells not stimulated with forskolin (7.8 ± 0.8 versus 3.8 ± 0.4 (USF1) and 13.0 ± 2.7 versus 3.4 ± 0.1 (USF2); p < 0.05) (Fig. 1B), suggesting the presence of some basal level of PKA activation in control cells. Thus, these results suggest that PKA activation is a potent regulator of USF-dependent PGHS-2 promoter activity in granulosa cells.

To study directly the role of PKA in USF-regulated PGHS-2 promoter activity, cPKA was overexpressed in cells cotransfected with –149/–2PGHS-2.LUC and U1wt or U2wt. The results show that cPKA overexpression caused a marked increase in USF1- and USF2-regulated PGHS-2 promoter activities, with 5.4- and 4.0-fold increases, respectively, compared with cells not transfected with cPKA (p < 0.05) (Fig. 2A). In contrast, cotransfections with vectors expressing CaMKII and CaMKIV, two kinases known to phosphorylate some transcription factors and to up-regulate gene transcription (41), had little or no effect on promoter activity. To investigate the role of the E-box in the cPKA-stimulated, USF-regulated PGHS-2 promoter, cotransfections were performed with –149/–2PGHS-2{Delta}E-box.LUC, which contains a mutated E-box element in the context of the –149/–2 PGHS-2 promoter fragment. The results reveal that mutation of the E-box element abolished USF1- and USF2-stimulated PGHS-2 promoter activities or severely repressed cPKA-stimulated activities (p < 0.05) (Fig. 2B). The PKA inhibitor H-89 decreased cPKA- and USF-stimulated PGHS-2 promoter activities in a dose-dependent manner, with the highest amount of H-89 (10 µM) causing an 88–94% reduction in promoter activities (p < 0.05) (Fig. 2C).



View larger version (21K):
[in this window]
[in a new window]
  		FIG. 1.
PKA activator- and USF-dependent regulation of the PGHS-2 promoter in granulosa cells. A, bovine granulosa cells were cotransfected with the promoterless plasmid pGL3-Basic (Basic) or –149/–2PGHS-2.LUC (–149/–2PGHS) in the absence or presence of the U1wt or U2wt expression construct as described under "Experimental Procedures." All cultures were cotransfected with the SV40 Renilla luciferase vector (pRL-SV40) as an internal control to normalize experimental reporter activity. After transfection, cells were cultured for 36 h in the absence (Control) or presence of forskolin (FSK; 10 µM), 8-Br-cAMP (1 mM), or PMA (100 nM). B, cotransfections were performed with –149/–2PGHS-2.LUC and the U1wt or U2wt expression vector. After transfection, cells were cultured for 36 h in the absence (Control) or presence of forskolin (10 µM) and the PKA inhibitor H-89 (10 µM). Results are presented as relative luciferase activity (firefly/Renilla; mean ± S.E. of triplicate cultures from four experiments).

 
As a complementary approach to study the role of the PKA pathway in the USF-dependent regulation of the PGHS-2 promoter, the effect of overexpression of PKI (42) was tested in granulosa cells transfected with USF expression vectors. The results reveal a dose-dependent reduction in PGHS-2 promoter activities with increasing amounts of PKI transfected, with the highest amount of PKI (25 pmol) resulting in 57–69 and 75–80% inhibition of basal and forskolin-dependent promoter activities, respectively, in USF1- or USF2-overexpressing cells (p < 0.05) (Fig. 3, A and B).

To determine whether the effects of PKA activators and inhibitors on PGHS-2 promoter activity relate to changes in mRNA levels, cells were cultured for 24 h in the absence or presence of forskolin, cPKA, H-89, or PKI, and reverse transcription-PCR analyses were performed to study changes in the levels of the PGHS-2 transcript. The results show that the levels of PGHS-2 mRNA were low in control cultures, but markedly increased after stimulation with forskolin or transfection with cPKA (Fig. 3C, lane 1 versus lanes 2 and 5, respectively). However, H-89 and PKI blocked the forskolin- and cPKA-stimulated expression of the PGHS-2 transcript (Fig. 3C, lanes 3, 4, and 6). In contrast, these treatments had little or no effect on the levels of USF1 and USF2 mRNAs (Fig. 3C).



View larger version (22K):
[in this window]
[in a new window]
  		FIG. 2.
Effect of cPKA overexpression on USF-regulated PGHS-2 promoter activity in granulosa cells. A, bovine granulosa cells were cotransfected with –149/–2PGHS-2.LUC (–149/–2PGHS) and U1wt or U2wt in the absence (–) or presence of the vector expressing cPKA, CaMKII, or CaMKIV as described under "Experimental Procedures." All cultures were cotransfected with the SV40 Renilla luciferase vector (pRL-SV40) as an internal control to normalize experimental reporter activity. B, cotransfections were performed with –149/–2PGHS-2{Delta}E-box.LUC (–149/–2PGHS{Delta}Ebox) and the U1wt or U2wt expression vector in the absence (–) or presence of the vector expressing cPKA. C, cotransfections were performed with –149/–2PGHS-2.LUC and cPKA in the absence (Control) or presence of U1wt or U2wt. After transfection, cells were incubated for 36 h in the absence or presence of graded doses (0–10 µM) of H-89. Results are presented as relative luciferase activity (firefly/Renilla; mean ± S.E. of triplicate cultures from three experiments).

 
Effect of U2{Delta}1–220 on PKA- and USF-dependent PGHS-2 Promoter and Protein/DNA Binding Activities—To further investigate the molecular basis for the regulation of the PGHS-2 promoter by USF proteins following PKA activation, promoter activity and protein/DNA binding assays were performed in the presence of the U2{Delta}1–220 expression construct, which encodes an N-terminally truncated form of USF2 lacking essential transactivation domains but containing dimerization and DNA-binding domains (34). The results show that simultaneous cotransfections with U2{Delta}1–220 and –149/–2PGHS-2.LUC had no effect on basal and forskolin-inducible PGHS-2 promoter activities, but caused a marked reduction in cPKA-mediated activities (p < 0.05) (Fig. 4A). In contrast, U2{Delta}1–220 blocked the basal, forskolin-, and cPKA-dependent PGHS-2 promoter activities in cultures transfected with the U1wt and U2wt expression constructs (p < 0.05) (Fig. 4A).

The ability of U2{Delta}1–220 to compete with full-length USF1 and USF2 for binding the PGHS-2 promoter was tested in vitro by EMSAs using nuclear extracts prepared from granulosa cells transfected with the truncated or wild-type USF expression vectors and the 32P-labeled –149/–2 PGHS-2 promoter fragment. A major protein·DNA complex was formed with extracts prepared from USF2-transfected (Fig. 4B, band a, lane 1) and U2{Delta}1–220-transfected (band b, lane 9) cells. As expected, the complex containing N-terminally truncated USF2 (Fig. 4B, band b) migrated faster than the complex containing full-length USF2 (band a). Competition assays clearly revealed the ability of increasing amounts of the U2{Delta}1–220 extract to displace full-length USF2 on the –149/–2 PGHS-2 promoter fragment (Fig. 4B, lanes 2–8). Moreover, U2{Delta}1–220 was able to displace full-length USF1, although not as efficiently as USF2 (Fig. 4C). EMSA performed with an extract prepared from mock-transfected granulosa cells confirmed the presence of a complex known to contain endogenous USF proteins (Fig. 4D, band d, lane 2) as shown previously (21, 33).



View larger version (20K):
[in this window]
[in a new window]
  		FIG. 3.
Effect of PKI overexpression on USF-dependent PGHS-2 promoter activity and mRNA levels in granulosa cells. Granulosa cells were cotransfected with –149/–2PGHS-2.LUC (–149/–2PGHS), U1wt (A) or U2wt (B), and the PKI expression vector (1–25 fmol) as described under "Experimental Procedures." After transfection, cells were cultured for 36 h in the absence (Control) or presence of forskolin (FSK;10 µM). All cultures were cotransfected with the SV40 Renilla luciferase vector (pRL-SV40) as an internal control to normalize experimental reporter activity. Results are presented as relative luciferase activity (firefly/Renilla; mean ± S.E. of triplicate cultures from three experiments). Granulosa cells were cultured in the absence (Control) or presence of forskolin (10 µM), H-89 (10 µM), or the vector expressing PKI or cPKA (C). After 24 h of treatment, RNA extracts were prepared, and changes in PGHS-2, USF1, USF2, or glyceraldehyde-3-phosphate dehydrogenase (GAPDH; internal control) mRNA were analyzed by reverse transcription-PCR as described under "Experimental Procedures."

 
To demonstrate the capacity of full-length USF2 and N-terminally truncated USF2 to interact with the endogenous PGHS-2 promoter in vivo, untransfected granulosa cells and those transfected with the U2wt or U2{Delta}1–220 expression vector were cultured in the absence or presence of forskolin, and protein/DNA interactions were studied by ChIP analyses. The results show that endogenous USF2, U2wt, and U2{Delta}1–220 effectively bound the PGHS-2 promoter in vivo (Fig. 5, lanes 3, 9, and 15, respectively). Interestingly, binding of full-length USF2 and truncated USF2 to the endogenous PGHS-2 promoter appeared to be increased after forskolin treatment (Fig. 5, lanes 6 versus lane 3 for endogenous USF2, lane 12 versus lane 9 for U2wt, and lane 18 versus lane 15 for U2{Delta}1–220). In contrast, negative controls employing normal rabbit serum instead of anti-USF2 antibody for ChIP revealed very low or no binding activity, as expected (Fig. 5, lanes 2, 5, 8, 11, 14, and 17).



View larger version (55K):
[in this window]
[in a new window]
  		FIG. 4.
Effect of dominant-negative U2{Delta}1–220 on PKA- and USF-regulated PGHS-2 promoter and protein/DNA binding activities in granulosa cells. A, granulosa cells were cotransfected with –149/–2PGHS-2.LUC (–149/–2PGHS) in the absence (–) or presence of the construct expressing U1wt, U2wt, U2{Delta}1–220, or cPKA as described under "Experimental Procedures." After transfection, cells were cultured for 36 h in the absence (Control) or presence of forskolin (FSK; 10 µM). All cultures were cotransfected with the SV40 Renilla luciferase vector (pRL-SV40) as an internal control to normalize experimental reporter activity. Results are presented as relative luciferase activity (firefly/Renilla; mean ± S.E. of triplicate cultures from three experiments). B and C, nuclear protein extracts were prepared from granulosa cells transfected with U2wt, U1wt, or U2{Delta}1–220 (4 µg of construct/100 mm dish) as described under "Experimental Procedures." Extracts from cells transfected with U2wt (0.5 µg/reaction) and U2{Delta}1–220 (0–1 µg/reaction) (B) or U1wt (0.5 µg/reaction) and U2{Delta}1–220 (0–1 µg/reaction) (C) were incubated with the 32P-labeled –149/–2 PGHS-2 promoter fragment, and protein/DNA interactions were studied by EMSAs. The precise amounts of U2{Delta}1–220 extract used in reactions in B and C were 0, 0.01, 0.025, 0.05, 0.1, 0.25, 0.5, 1.0, and 0.05 µg for lanes 1–9, respectively. D, reactions were performed in the absence (lane 1) and presence (lane 2) of nuclear extract (8 µg/reaction) prepared from mock-transfected granulosa cells. Binding reactions were resolved by 5% PAGE with 0.5x TBE (100 nM Tris, 100 mM borate, and 2 mM EDTA). For reference purposes, the U2wt·DNA, U1wt·DNA, U2{Delta}1–220·DNA, and endogenous USF·DNA complexes are designated as bands a–d, respectively.

 
Phosphorylation Status of USF Proteins and Its Effect on Protein/DNA Binding Activities—To further investigate whether changes in PKA-dependent phosphorylation alter the ability of USF proteins to bind to the PGHS-2 promoter, EMSAs were performed with the –149/–2 PGHS-2 promoter fragment and nuclear extracts obtained from USF-transfected granulosa cells cultured in the absence or presence of forskolin or cotransfected with the cPKA or PKI expression vector. Alternatively, the effect of protein dephosphorylation on USF/DNA binding activity was studied by EMSAs with cell extracts treated with phosphatase. The results show that the intensity of the major protein·DNA complex formed with the USF2 cell extract increased after forskolin treatment or cPKA overexpression (Fig. 6A, band a, lane 4 versus lanes 5 and 6, respectively), but markedly decreased after PKI overexpression (band a, lane 4 versus lane 7). Likewise, the complex formed with extracts from USF2-transfected cells was reduced after phosphatase treatment in control (Fig. 6A, lane 4 versus lane 1), forskolin-treated (lane 5 versus lane 2), and cPKA-treated (lane 6 versus lane 3) cells. Comparable results were obtained when identical treatments were performed with cells transfected with full-length USF1, albeit some of the effects were more modest (Fig. 6B). Similar studies performed with N-terminally truncated USF2 construct U2{Delta}1–220 showed that the intensity of the protein·DNA complex increased after forskolin and cPKA transfection (Fig. 6C, band c, lane 1 versus lanes 2 and 3, respectively), but decreased after PKI transfection (band c, lane 1 versus lane 4, respectively). Phosphatase treatment reduced the formation of the U2{Delta}1–220 protein·DNA complex in control (Fig. 6C, lane 1 versus lane 5), forskolin-treated (lane 2 versus lane 6), and cPKA-treated (lane 3 versus lane 7) cells. Similar results were observed with the N-terminally truncated USF1 construct U1{Delta}1–129 (Fig. 6D).

To characterize the phosphorylation status of USF proteins in granulosa cells, nuclear protein extracts were prepared from untransfected cells and USF-overexpressing cells before and after stimulation with forskolin in vitro or hCG in vivo. Immunoprecipitation was performed with specific anti-USF antibodies, and immunoprecipitated proteins were analyzed by Western blotting with anti-phosphoserine and anti-phosphothreonine antibodies. The results reveal that the levels of phosphorylated USF1 were very low in unstimulated cells transfected with the USF1 expression vector, but increased after forskolin treatment (Fig. 7A, lane 2 versus lane 3). The levels of USF2 phosphorylated at serine and threonine residues were moderate in control cells transfected with the USF2 construct, but appeared to increase after forskolin treatment (Fig. 7A, lane 4 versus lane 5). When identical experiments were performed with cells overexpressing N-terminally truncated USF proteins, the levels of phosphorylated U1{Delta}1–129 and U2{Delta}1–220 were markedly increased after forskolin treatment (Fig. 7B, lane 2 versus lane 3 for U1{Delta}1–129 and lane 4 versus lane 5 for U2{Delta}1–220). Likewise, experiments performed with untransfected granulosa cells revealed that the levels of endogenous phosphorylated USF1 and USF2 rose after forskolin stimulation (Fig. 7C, lane 2 versus lane 5 for USF1 and lane 3 versus lane 6 for USF2). Interestingly, a similar pattern was observed in nuclear extracts of granulosa cells obtained from preovulatory follicles isolated before and after hCG treatment, with the results showing an increase in phosphorylated USF1 and USF2 18 h after hCG treatment (Fig. 7D, lane 2 versus lane 4 for USF1 and lane 3 versus lane 5 for USF2). In all studies, immunoprecipitation with normal rabbit serum failed to reveal an immunoreactive signal, as expected (Fig. 7, A, B, and D, lanes 1; and C, lanes 1 and 4).



View larger version (46K):
[in this window]
[in a new window]
  		FIG. 5.
ChIP analysis of USF/E-box binding activity within the PGHS-2 promoter. Untransfected granulosa cells (upper panel) and granulosa cells transfected with the U2wt (lower left panel) or U2{Delta}1–220 (lower right panel) expression construct were cultured for 36 h in the absence (Control) or presence of forskolin (FSK;10 µM). Cell lysates were prepared, and endogenous USF2, U2wt, or U2{Delta}1–220 interactions with the endogenous PGHS-2 promoter was studied by ChIP analysis as described under "Experimental Procedures." One-third of each chromatin extract was kept as DNA input control (Input) before immunoprecipitation; one-third was precipitated with anti-USF2 antibody directed against its C terminus (Anti-USF2); and the remaining third was incubated with normal rabbit serum (NRS) and served as a negative control. A 180-bp DNA fragment containing the E-box cis-element present within the bovine PGSH-2 promoter was amplified by PCR.

 
Effect of USF Phosphorylation Site Mutants on PGHS-2 Promoter Activity—Inspection of USF1 and USF2 amino acid sequences with the phosphorylation site prediction server Net Phas 2.0 (available at www.cbs.dtu.dk) revealed several putative phosphorylatable residues; however, only one serine residue in USF1 (Ser257) and one in USF2 (Ser259) were identified as putative consensus PKA phosphorylation sites. To determine their potential involvement in USF action on PGHS-2 promoter activity, PCR-based site-directed mutagenesis was used to substitute the phosphorylatable serine with a nonphosphorylatable alanine, and single point mutants were tested in promoter activity assays. The results show that the substitution of Ser257 with Ala in USF1 (U1S257A) severely impaired basal (5.6 ± 0.5 (U1wt) versus 1.7 ± 0.3 (U1S257A)) and forskolin-dependent (25.4 ± 2.6 (U1wt) versus 8.8 ± 0.8 (U1S257A)) PGHS-2 promoter activities (p < 0.05) (Fig. 8). Similarly, the substitution of Ser259 with Ala in USF2 (U2S259A) markedly decreased basal (17.8 ± 2.7 (U2wt) versus 2.1 ± 0.3 (U2S259A)) and forskolin-dependent (39.5 ± 2.4 (U2wt) versus 9.8 ± 1.6 (U2S259A)) PGHS-2 promoter activities (p < 0.05) (Fig. 8). The levels of PGHS-2 promoter activities observed in the presence of U1S257A and U2S259A were not significantly different from those in cells not transfected with the USF constructs, suggesting that this single point mutation rendered the mutant constructs nonfunctional (Fig. 8). In contrast, substitutions of Ser262 in USF1 (U1S262A) and of Ser269 or Ser275 in USF2 (U2S269A and U2S275A, respectively) had no marked effect and led to PGHS-2 promoter activities very similar to those with wild-type USF constructs (Fig. 8).



View larger version (84K):
[in this window]
[in a new window]
  		FIG. 6.
Regulation of USF/E-box binding activities by PKA activation and inhibition and by phosphatase treatment. Nuclear protein extracts were prepared from granulosa cells transfected with the U2wt (A), U1wt (B), U2{Delta}1–220 (C), or U1{Delta}1–129 (D) expression vector as described under "Experimental Procedures." Cells were cultured in the absence (Control) or presence of forskolin (FSK) or were cotransfected with the cPKA or PKI expression vector prior to the preparation of extracts. In some reactions, nuclear extracts were pretreated with phosphatase (1 IU, 10 min) prior to addition of other reagents. Extracts were incubated with the 32P-labeled –149/–2 PGHS-2 promoter fragment, and protein/DNA interactions were studied by EMSAs. Binding reactions were resolved by 5% PAGE with 0.5x TBE. For reference purposes, the major U2wt·DNA (A), U1wt·DNA (B), U2{Delta}1–220·DNA (C), and U1{Delta}1–129·DNA (D) complexes are designated as bands a–d, respectively.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Ovulation has been compared with an acute self-controlled inflammatory reaction, as both processes share similar phenomena such as hyperemia, edema, leukocyte extravasation, and tissue damage and repair (4, 43). The biosynthesis of prostaglandins, which are known mediators of inflammation, has been shown to be essential for the process of follicular rupture, with the induction of PGHS-2 in granulosa cells appearing as the underlying mechanism responsible for increased follicular prostaglandins prior to ovulation (8–14). Previous studies identified USF transactivating factors and a proximal E-box cis-acting element as predominant regulators of the PGHS-2 promoter in granulosa cells of rat and bovine preovulatory follicles (21, 23, 33). However, analyses in both species revealed that endogenous levels of full-length USF1 and USF2 proteins do not vary in granulosa cells during the ovulatory process (21, 23), thus raising questions regarding potential additional mechanisms involved in USF-dependent regulation of the PGHS-2 promoter. The present study has provided evidence that the phosphorylation status of USF proteins is involved in the regulation of the PGHS-2 promoter in granulosa cells. As a working model, we propose that the preovulatory surge of luteinizing hormone, which is the primary trigger of the ovulatory cascade, activates the luteinizing hormone receptor/adenylyl cyclase/cAMP/PKA pathway, leading to USF phosphorylation, increased USF binding to the E-box, and enhanced PGHS-2 promoter transactivation. This model does not preclude some contribution by other cis-elements and transcription factors or coactivators, but additional studies will be required to address this issue.



View larger version (34K):
[in this window]
[in a new window]
  		FIG. 7.
Immunoprecipitation/Western blot analyses of phosphorylated USF proteins in granulosa cells in vitro and in vivo. A, nuclear extracts were prepared from granulosa cells transfected with U1wt or U2wt and cultured in the absence (–) or presence (+) of forskolin (FSK). Extracts (10 µg of protein/reaction) were first immunoprecipitated with normal rabbit serum (NRS) or anti-USF1 (Anti-U1) or anti-USF2 (Anti-U2) antibody and then subjected to Western blot analyses using anti-phosphoserine (Anti-PS) or anti-phosphothreonine (Anti-PT) antibody as described under "Experimental Procedures." B, nuclear extracts (10 µg of protein/reaction) prepared from granulosa cells transfected with the U1{Delta}1–129 or U2{Delta}1–220 expression vector and cultured in the absence (–) or presence (+) of forskolin were subjected to immunoprecipitation and Western blot analyses as described for A. C, nuclear extracts were prepared from untransfected granulosa cells cultured for 0 and 36 h with forskolin (10 µM) and subjected to immunoprecipitation and Western blot analyses as described for A. D, extracts of nuclear proteins were prepared from granulosa cells of preovulatory follicles isolated 0 and 18 h after an ovulatory dose of hCG and subjected to immunoprecipitation and Western blot analyses as described for A.

 
The biological activity of transcription factors is often regulated by post-translational modifications, with protein phosphorylation being one the most common post-translational modifications in eukaryotic cells. Phosphorylation has been shown to positively affect the transactivating capacity of various transcription factors, including cAMP response element-binding protein, GATA, NF-{kappa}B, peroxisome proliferator-activated receptors, and steroid hormone receptors (44–49). Notable, USF phosphorylation has been linked to increased E-box binding activity and enhanced promoter activation for other genes such as the tyrosinase, cardiac {alpha}-myosin heavy chain, C4 complement, and telomerase reverse transcriptase genes (30, 35, 36, 50). However, a potential relationship between USF phosphorylation and PGHS-2 gene expression has not been established. The present study has provided complementary evidence for a link between PKA-mediated USF phosphorylation and PGHS-2 promoter transactivation in granulosa cells. Such evidence includes the ability of forskolin, 8-Br-cAMP, and cPKA to stimulate and the capacity of H-89 and PKI to inhibit USF-regulated PGHS-2 promoter activities. Furthermore, the results from immunoprecipitation/Western blot analyses indicate that the amount of phosphorylated USF proteins was increased by forskolin/hCG in granulosa cells in vitro and in vivo. One putative consequence of PKA-dependent USF phosphorylation is the apparent increase in USF binding affinity for the E-box promoter element, as observed by EMSA and ChIP analyses, thus providing a likely biochemical basis for the enhanced PGHS-2 promoter activity. In contrast, activation of the PKC pathway with PMA had no stimulatory effect on PGHS-2 promoter activity, in keeping with previous studies that revealed the incapacity of PKC activators to regulate the PGHS-2 promoter in bovine and ovine preovulatory granulosa cells (51, 52). The prevalent role of the protein kinase A pathway in the regulation of the PGHS-2 promoter in bovine preovulatory granulosa cells is further underscored by the lack of effect of CaMKII and CaMKIV, two Ca2+/calmodulin-dependent protein kinases known to activate the transcription of other genes (41, 53–56). Ultimately, the functional inactivation of USF proteins through a single point mutation within the USF1 (U1S257A) and USF2 (U2S259A) PKA phosphorylation sites provided further evidence for a relationship between PKA-mediated USF phosphorylation and PGHS-2 gene expression.



View larger version (42K):
[in this window]
[in a new window]
  		FIG. 8.
Effect of USF1 and USF2 phosphorylation site mutants on PGHS-2 promoter activities. A, bovine granulosa cells were cotransfected with the promoterless plasmid pGL3-Basic (Basic) or –149/–2PGHS-2.LUC (–149/–2PGHS) in the absence (–) or presence of the U2wt or U1wt expression construct; USF1 phosphorylation site mutant U1S257A or U1S262A; or USF2 phosphorylation site mutant U2S259A, U2S269A, or U2S275A as described under "Experimental Procedures." All cultures were cotransfected with the SV40 Renilla luciferase vector (pRL-SV40) as an internal control to normalize experimental reporter activity. After transfection, cells were cultured for 24 h in the absence (Control) or presence of forskolin (FSK;10 µM). Results are presented as relative luciferase activity (firefly/Renilla; mean ± S.E. of triplicate cultures from four experiments). B, shown is a list of the sense (S) and antisense (AS) mutagenic oligonucleotide primers used to generate USF1 (U1S257A and U1S262A) and USF2 (U2S259A, U2S269A, and U2S275A) phosphorylation site mutants. For each construct, a putative phosphorylatable serine residue was replaced with a non-phosphorylatable alanine residue using the QuikChange site-directed mutagenesis kit as described under "Experimental Procedures." Lowercase letters indicate nucleotide changes introduced into the USF sequence.

 
One remarkable feature regarding the control of PGHS-2 gene expression is the large variety of agonists known to stimulate its transcription, including numerous pro-inflammatory mediators, growth factors, oncogenes, and protein and steroid hormones (reviewed in Refs. 57 and 58). The 5'-flanking promoter region of the PGHS-2 gene contains a number of consensus cis-acting elements; of these, the cAMP response, NF-IL6 (CCAAT/enhancer-binding protein), and NF-{kappa}B elements have often been shown to direct the inflammatory/mitogenesis/oncogenesis-dependent induction of PGHS-2 in various cell types (57–65). In contrast, the E-box element present within the proximal promoter region was not found to participate in PGHS-2 promoter activation (63, 65–67), except in few cases, such as in skin carcinoma cells, macrophages, and gastric epithelial cells (68–70). One notable exception is also the gonadotropin-dependent induction of PGHS-2 in rat and bovine granulosa cells, in which the E-box was shown to play a central role (21, 23, 33, 52). Indeed, a previous study showed that mutation of the E-box element results in a 91–92% reduction in basal and forskolin-dependent PGHS-2 promoter activities in bovine granulosa cells, whereas mutation of the bovine cAMP response element/activating transcription factor has no deleterious effect (21). The results from the present study confirm the key role of the E-box in granulosa cells because its mutation abolished USF-dependent PGHS-2 promoter activation. Moreover, the marked increase in PGHS-2 promoter activity caused by cPKA in USF-transfected cells was also severely repressed (>92%) when the E-box was mutated, clearly indicating the central function of the cis-element.

Overexpression of N-terminally truncated USF proteins served as an important approach to further characterize the potential role of protein phosphorylation in the regulation of the PGHS-2 promoter. These truncated proteins, U2{Delta}1–220 and U1{Delta}1–129 (33), lack N-terminal transactivation domains but contain the basic helix-loop-helix and leucine zipper domains responsible for dimerization and DNA binding activities (24, 25, 71). The results showing the ability of overexpressed U2{Delta}1–220 to block cPKA-regulated PGHS-2 promoter activities under basal conditions as well as forskolin- and cPKA-regulated PGHS-2 promoter activities in cells overexpressing USF1 or USF2 were of particular interest. These findings suggest that the phosphorylation events induced by cPKA and responsible for regulating the PGHS-2 promoter involve primarily USF proteins. It should also be noted that, under the present experimental conditions of simultaneous cotransfections of U2{Delta}1–220 and –149/–2PGHS-2.LUC, the inability of U2{Delta}1–220 to attenuate the forskolin-dependent activation of the PGHS-2 promoter in the absence of USF overexpression was expected, in keeping with a previous report (33). A rapid forskolin-dependent modification/activation of existing endogenous USF proteins prior to expression of sufficient USF mutant was proposed as the likely basis for this outcome. Indeed, experiments in which overexpression of U2{Delta}1–220 was allowed to proceed for 24 h prior to transfection of the promoter construct and stimulation with forskolin clearly revealed the ability of the mutant to block activation of the PGHS-2 promoter (33).

EMSAs indicated that U2{Delta}1–220 was able to compete with full-length USF proteins and saturate the E-box element and thus provided evidence for a plausible mechanism of action for this dominant-negative mutant. Interestingly, as observed for full-length proteins, the phosphorylation status of U2{Delta}1–220 and U1{Delta}1–129 seemed to affect their binding to the E-box. Indeed, forskolin treatment and cPKA overexpression increased and phosphatase treatment and PKI overexpression reduced the formation of truncated USF·DNA complexes in vitro. The forskolin-dependent phosphorylation of U2{Delta}1–220 and U1{Delta}1–129 was confirmed by immunoprecipitation/Western blot analyses, whereas ChIP assays clearly pointed to an increase in binding of U2{Delta}1–220 to the endogenous PGHS-2 promoter after forskolin treatment. The identification of functional PKA-dependent phosphorylation sites at Ser259 in full-length USF2 and at Ser257 in full-length USF1 is in keeping with a key role of the C terminus of USF proteins in PGHS-2 promoter binding and activation.

In summary, the present study has characterized for the first time a relationship between USF phosphorylation and PGHS-2 promoter activation in granulosa cells and has identified USF phosphorylation as a likely biochemical consequence of the activation of the PKA pathway by the luteinizing hormone preovulatory surge (72). The present investigation also established the apparent requirements for the control of PGHS-2 gene expression in granulosa cells, including an active cAMP/PKA signaling pathway, intact USF proteins, and a consensus E-box element. Although activation of the PKA pathway is an important trigger of this biochemical cascade, the potential downstream activation of other signaling pathways should also be considered (73). Last, a more comprehensive understanding of the molecular mechanisms involved in PGHS-2 gene expression in preovulatory granulosa cells will need to consider the potential involvement of transcriptional coactivators and chromatin epigenetic regulators.


   FOOTNOTES
 
* This work was supported in part by Canadian Institutes of Health Research Grant MT-13190 (to J. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} Supported by a Canadian Institutes of Health Research investigator award. To whom correspondence should be addressed: CRRA, Faculté de Médecine Vétérinaire, Université de Montréal, 3200 Sicotte, C. P. 5000, Saint-Hyacinthe, Québec J2S 7C6, Canada. Tel.: 450-773-8521 (ext. 8542); Fax: 450-778-8103; E-mail: jean.sirois{at}umontreal.ca.

1 The abbreviations used are: PGHS, prostaglandin G/H synthase; PKA, protein kinase A; USF, upstream stimulatory factor; EMSA, electrophoretic mobility shift assay; 8-Br-cAMP, 8-bromo-cAMP; cPKA, catalytic subunit of PKA; PKI, PKA inhibitor protein; CaMK, Ca2+/calmodulin-dependent protein kinase; wt, wild-type; LUC, luciferase; PMA, phorbol 12-myristate 13-acetate; ChIP, chromatin immunoprecipitation; hCG, human chorionic gonadotropin. Back


   ACKNOWLEDGMENTS
 
We thank Dr. Richard Maurer for the generous gift of vectors expressing cPKA, PKI, CaMKII, and CaMKIV and Danielle Rannoux for technical assistance with the collection of ovaries.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Armstrong, D. T. (1981) J. Reprod. Fertil. 62, 283–291[Abstract/Free Full Text]
  2. Murdoch, W. J., Hansen, T. R., and McPherson, L. A. (1993) Prostaglandins 46, 85–115[CrossRef][Medline] [Order article via Infotrieve]
  3. Sirois, J., Sayasith, K., Brown, K. A., Stock, A. E., Bouchard, N., and Dore, M. (2004) Hum. Reprod. Update. 10, 373–385[Abstract/Free Full Text]
  4. Espey, L. L., and Lipner, H. (1994) in Physiology of Reproduction (Knobil, E., and Neil, J. D., eds) Vol. 1, pp. 725–781, Raven Press, Ltd., New York
  5. Hedin, L., Gaddy-Kurten, D., Kurten, R., DeWitt, D. L., Smith, W. L., and Richards, J. S. (1987) Endocrinology 121, 722–731[Abstract/Free Full Text]
  6. Huslig, R. L., Malik, A., and Clark, M. R. (1987) Mol. Cell. Endocrinol. 50, 237–246[CrossRef][Medline] [Order article via Infotrieve]
  7. Wong, W. Y., and Richards, J. S. (1991) Mol. Endocrinol. 5, 1269–1279[Abstract/Free Full Text]
  8. Sirois, J., and Richards, J. S. (1992) J. Biol. Chem. 267, 6382–6388[Abstract/Free Full Text]
  9. Sirois, J., Simmons, D. L., and Richards, J. S. (1992) J. Biol. Chem. 267, 11586–11592[Abstract/Free Full Text]
  10. Sirois, J. (1994) Endocrinology 135, 841–848[Abstract]
  11. Tsai, S. J., Wiltbank, M. C., and Bodensteiner, K. J. (1996) Endocrinology 137, 3348–3355[Abstract]
  12. Sirois, J., and Dore, M. (1997) Endocrinology 138, 4427–4434[Abstract/Free Full Text]
  13. Joyce, I. M., Pendola, F. L., O'Brien, M., and Eppig, J. J. (2001) Endocrinology 142, 3187–3197[Abstract/Free Full Text]
  14. Duffy, D. M., and Stouffer, R. L. (2002) Hum. Reprod. 17, 2825–2831[Abstract/Free Full Text]
  15. Segi, E., Haraguchi, K., Sugimoto, Y., Tsuji, M., Tsunekawa, H., Tamba, S., Tsuboi, K., Tanaka S., and Ichikawa, A. (2003) Biol. Reprod. 68, 804–811[Abstract/Free Full Text]
  16. Lim, H., Paria, B. C., Das, S. K., Dinchuk, J. E., Langenbach, R., Trzaskos, J. M., and Dey, S. K. (1997) Cell 91, 197–208[CrossRef][Medline] [Order article via Infotrieve]
  17. Davis, B. J., Lennard, D. E., Lee, C. A., Tiano, H. F., Morham, S. G., Wetsel, W. C., and Langenbach, R. (1999) Endocrinology 140, 2685–2695[Abstract/Free Full Text]
  18. Reese, J., Zhao, X., Ma, W. G., Brown, N., Maziasz, T. J., and Dey, S. K. (2001) Endocrinology 142, 3198–3206[Abstract/Free Full Text]
  19. Wang, H., Ma, W. G., Tejada, L., Zhang, H., Morrow, J. D., Das, S. K., and Dey, S. K. (2004) J. Biol. Chem. 279, 10649–10658[Abstract/Free Full Text]
  20. Wong, W. Y., DeWitt, D. L., Smith, W. L., and Richards, J. S. (1989) Mol. Endocrinol. 3, 1714–1723[Abstract/Free Full Text]
  21. Liu, J., Antaya, M., Boerboom, D., Lussier, J. G., Silversides, D. W., and Sirois, J. (1999) J. Biol. Chem. 274, 35037–35045[Abstract/Free Full Text]
  22. Sirois, J., Levy, L. O., Simmons, D. L., and Richards, J. S. (1993) J. Biol. Chem. 268, 12199–12206[Abstract/Free Full Text]
  23. Morris, J. K., and Richards, J. S. (1996) J. Biol. Chem. 271, 16633–16643[Abstract/Free Full Text]
  24. Gregor, P. D., Sawadogo, M., and Roeder, R. G. (1990) Genes Dev. 4, 1730–1740[Abstract/Free Full Text]
  25. Sirito, M., Walker, S., Lin, Q., Kozlowski, M. T., Klein, W. H., and Sawagado, M. (1992) Gene Expr. 2, 231–240[Medline] [Order article via Infotrieve]
  26. Harris, A. N., and Mellon, P. L. (1998) Mol. Endocrinol. 12, 714–726[Abstract/Free Full Text]
  27. Jiang, B., and Mendelson, C. R. (2003) Mol. Cell. Biol. 23, 6117–6128[Abstract/Free Full Text]
  28. Zhu, J., Giannola, D. M., Zhang, Y., Rivera, A. J., and Emerson, S. G. (2003) Blood 102, 2420–2427[Abstract/Free Full Text]
  29. Szentirmay, M. N., Yang, H. X., Pawar, S. A., Vinson, C., and Sawadogo, M. (2003) J. Biol. Chem. 278, 37231–37240[Abstract/Free Full Text]
  30. Goueli, B. S., and Janknecht, R. (2003) Oncogene 22, 8042–8047[CrossRef][Medline] [Order article via Infotrieve]
  31. Okada, Y., Matsuura, E., Tozuka, Z., Nagai, R., Watanabe, A., Matsumoto, K., Yasui, K., Jackman, R. W., Nakano, T., and Doi, T. (2004) Blood 104, 2027–2034[Abstract/Free Full Text]
  32. Kanamoto, N., Akamizu, T., Tagami, T., Hataya, Y., Moriyama, K., Takaya, K., Hosoda, H., Kojima, M., Kangawa, K., and Nakao, K. (2004) Endocrinology 145, 4144–4153[Abstract/Free Full Text]
  33. Sayasith, K., Bouchard, N., Sawadogo, M., Lussier, J. G., and Sirois, J. (2004) J. Biol. Chem. 279, 6327–6336[Abstract/Free Full Text]
  34. Cheung, E., Mayr, P., Coda-Zabetta, F., Woodman, P. G., and Boam, D.S. (1999) Biochem. J. 344, 145–152[CrossRef][Medline] [Order article via Infotrieve]
  35. Galibert, M. D., Carreira, S., and Goding, C. R. (2001) EMBO J. 20, 5022–5031[CrossRef][Medline] [Order article via Infotrieve]
  36. Xiao, Q., Kenessey, A., and Ojamaa, K. (2002) Am. J. Physiol. 283, H213–H219
  37. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254[CrossRef][Medline] [Order article via Infotrieve]
  38. Liu, J., and Sirois, J. (1998) Biol. Reprod. 58, 1527–1532[Abstract/Free Full Text]
  39. Brûlé, S., Faure, R., Doré, M., Silversides D. W., and Lussier, J. G. (2003) Histochem. Cell Biol. 119, 371–381[CrossRef][Medline] [Order article via Infotrieve]
  40. Naz, R. K. (1999) Biol. Reprod. 60, 1402–1409[Abstract/Free Full Text]
  41. Sun, P., Lou, L., and Maurer, R. A. (1996) J. Biol. Chem. 271, 3066–3073[Abstract/Free Full Text]
  42. Day, R. N., Walder, J. A., and Maurer, R. A. (1989) J. Biol. Chem. 264, 431–436[Abstract/Free Full Text]
  43. Espey, L. L. (1980) Biol. Reprod. 22, 73–106[CrossRef][Medline] [Order article via Infotrieve]
  44. Katzenellenbogen, B. S., and Katzenellenbogen, J. A. (2000) Breast Cancer Res. 2, 335–344[CrossRef][Medline] [Order article via Infotrieve]
  45. Blanquart, C., Barbier, O., Fruchart, J. C., Staels, B., and Glineur, C. (2003) J. Steroid Biochem. Mol. Biol. 85, 267–273[CrossRef][Medline] [Order article via Infotrieve]
  46. Vanden Berghe, W., Vermeulen, L., Delerive, P., De Bosscher, K., Staels, B., and Haegeman, G. (2003) Adv. Exp. Med. Biol. 544, 181–196[Medline] [Order article via Infotrieve]
  47. Tremblay, J. J., and Viger, R. S. (2003) J. Steroid Biochem. Mol. Biol. 85, 291–298[CrossRef][Medline] [Order article via Infotrieve]
  48. Johannessen, M., Delghandi, M. P., and Moens, U. (2004) Cell. Signal. 16, 1211–1227[CrossRef][Medline] [Order article via Infotrieve]
  49. Lange, C. A. (2004) Mol. Endocrinol. 18, 269–278[Abstract/Free Full Text]
  50. Galibert, M. D., Boucontet, L., Goding, C. R., and Meo, T. (1997) J. Immunol. 159, 6176–6183[Abstract]
  51. Wu, Y. L., and Wiltbank, M. C. (2001) Prostaglandins Other Lipid Mediat. 65, 103–116[CrossRef][Medline] [Order article via Infotrieve]
  52. Wu, Y. L., and Wiltbank, M. C. (2002) Biol. Reprod. 66, 1505–1514[Abstract/Free Full Text]
  53. Lobo, F. M., Zanjani, R., Ho, N., Chatila, T. A., and Fuleihan, R. L. (1999) J. Immunol. 162, 2057–2063[Abstract/Free Full Text]
  54. Wu, H., Kanatous, S. B., Thurmond, F. A., Gallardo, T., Isotani, E., Bassel-Duby, R., and Williams, R. S. (2002) Science 296, 349–352[Abstract/Free Full Text]
  55. Nomura, K., Takeuchi, Y., Yamaguchi, S., Okamura, H., and Fukunaga, K. (2003) J. Neurosci. Res. 72, 384–392[Medline] [Order article via Infotrieve]
  56. Seals, R. C., Urban, R. J., Sekar, N., and Veldhuis, J. D. (2004) Endocrinology 145, 5616–5622[Abstract/Free Full Text]
  57. Tanabe, T., and Tohnai, N. (2002) Prostaglandins Other Lipid Mediat. 68–69, 95–114
  58. Chun, K. S., and Surh, Y. J. (2004) Biochem. Pharmacol. 68, 1089–1100[CrossRef][Medline] [Order article via Infotrieve]
  59. Inoue, H., Nanayama, T., Hara, S., Yokoyama, C., and Tanabe, T. (1994) FEBS Lett. 350, 51–54[CrossRef][Medline] [Order article via Infotrieve]
  60. Xie, W., Fletcher, B. S., Andersen, R. D., and Herschman, H. R. (1994) Mol. Cell. Biol. 14, 6531–6539[Abstract/Free Full Text]
  61. Inoue, H., Yokoyama, C., Hara, S., Tone, Y., and Tanabe, T. (1995) J. Biol. Chem. 270, 24965–24971[Abstract/Free Full Text]
  62. Crofford, L. J., Tan, B., McCarthy, C. J., and Hla, T. (1997) Arthritis Rheum. 40, 226–236[Medline] [Order article via Infotrieve]
  63. Schmedtje, J. F., Jr., Ji, Y. S., Liu, W. L., DuBois, R. N., and Runge, M. S. (1997) J. Biol. Chem. 272, 601–608[Abstract/Free Full Text]
  64. Reddy, S. T., Wadleigh, D. J., and Herschman, H. R. (2000) J. Biol. Chem. 275, 3107–3113[Abstract/Free Full Text]
  65. Wadleigh, D. J., Reddy, S. T., Kopp, E., Ghosh, S., and Herschman, H. R. (2000) J. Biol. Chem. 275, 6259–6266[Abstract/Free Full Text]
  66. Ogasawara, A., Arakawa, T., Kaneda, T., Takuma, T., Sato, T., Kaneko, H., Kumegawa, M., and Hakeda, Y. (2001) J. Biol. Chem. 276, 7048–7054[Abstract/Free Full Text]
  67. Billack, B., Heck, D. E., Mariano, T. M., Gardner, C. R., Sur, R., Laskin, D. L., and Laskin, J. D. (2002) Am. J. Physiol. 283, C1267–C1277
  68. Kim, Y., and Fischer, S. M. (1998) J. Biol. Chem. 273, 27686–27694[Abstract/Free Full Text]
  69. Mestre, J. R., Rivadeneira, D. E., Mackrell, P. J., Duff, M., Stapleton, P. P., Mack-Strong, V., Maddali, S., Smyth, G. P., Tanabe, T., and Daly, J. M. (2001) FEBS Lett. 496, 147–151[CrossRef][Medline] [Order article via Infotrieve]
  70. Juttner, S., Cramer, T., Wessler, S., Walduck, A., Gao, F., Schmitz, F., Wunder, C., Weber, M., Fischer, S. M., and Schmidt, W. E., Wiedenmann, B., Meyer, T. F., Naumann, M., and Hocker, M. (2003) Cell. Microbiol. 5, 821–834[CrossRef][Medline] [Order article via Infotrieve]
  71. Sirito, M., Lin, Q., Maity, T., and Sawagado, M. (1994) Nucleic Acids Res. 22, 425–433
  72. Ascoli, M., Fanelli, F., and Segaloff, D. L. (2002) Endocr. Rev. 23, 141–174[Abstract/Free Full Text]
  73. Richards, J. S., Russell, D. L., Ochsner, S., Hsieh, M., Doyle, K. H., Falender, A. E., Lo, Y. K., and Sharma, S. C. (2002) Recent Prog. Horm. Res. 57, 195–220[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 Nucleic Acids ResHome page
K. Kikuchi, M. Fukuda, T. Ito, M. Inoue, T. Yokoi, S. Chiku, T. Mitsuyama, K. Asai, T. Hirose, and Y. Aizawa
Transcripts of unknown function in multiple-signaling pathways involved in human stem cell differentiation
Nucleic Acids Res., June 16, 2009; (2009) gkp426v1.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
M. Kouzu-Fujita, Y. Mezaki, S. Sawatsubashi, T. Matsumoto, I. Yamaoka, T. Yano, Y. Taketani, H. Kitagawa, and S. Kato
Coactivation of Estrogen Receptor {beta} by Gonadotropin-Induced Cofactor GIOT-4
Mol. Cell. Biol., January 1, 2009; 29(1): 83 - 92.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. Sayasith, N. Bouchard, M. Dore, and J. Sirois
Regulation of Bovine Tumor Necrosis Factor-{alpha}-Induced Protein 6 in Ovarian Follicles during the Ovulatory Process and Promoter Activation in Granulosa Cells
Endocrinology, December 1, 2008; 149(12): 6213 - 6225.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
K.-Y. Park and A. F. Russo
Control of the Calcitonin Gene-related Peptide Enhancer by Upstream Stimulatory Factor in Trigeminal Ganglion Neurons
J. Biol. Chem., February 29, 2008; 283(9): 5441 - 5451.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
D. L. Russell and R. L. Robker
Molecular mechanisms of ovulation: co-ordination through the cumulus complex
Hum. Reprod. Update, May 1, 2007; 13(3): 289 - 312.
[Abstract] [Full Text] [PDF]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
S. Imagawa, S. Fujii, J. Dong, T. Furumoto, T. Kaneko, T. Zaman, Y. Satoh, H. Tsutsui, and B. E Sobel
Hepatocyte Growth Factor Regulates E Box-Dependent Plasminogen Activator Inhibitor Type 1 Gene Expression in HepG2 Liver Cells
Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2407 - 2413.
[Abstract] [Full Text] [PDF]

Home page
 Biol. Reprod.Home page
M. N. Diouf, K. Sayasith, R. Lefebvre, D. W. Silversides, J. Sirois, and J. G. Lussier
Expression of Phospholipase A2 Group IVA (PLA2G4A) Is Upregulated by Human Chorionic Gonadotropin in Bovine Granulosa Cells of Ovulatory Follicles
Biol Reprod, June 1, 2006; 74(6): 1096 - 1103.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
280/32/28885    most recent
M413434200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sayasith, K.
Right arrow Articles by Sirois, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sayasith, K.
Right arrow Articles by Sirois, J.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2005 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement